cutaneous squamous cell carcinoma
FDA Approves Unloxcyt for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
The FDA approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics), a programmed death ligand-1 (PD-L1) blocking ...
DECEMBER 16, 2024
Keytruda Gains Indication for Locally Advanced Squamous Cell Carcinoma
The FDA approved an additional indication for pembrolizumab (Keytruda, Merck)—monotherapy for locally ...
JULY 13, 2021
Keytruda Approved for Recurrent or Metastatic Cutaneous Squamous Cell Cancer
The FDA approved pembrolizumab (Keytruda, Merck) for patients with recurrent or metastatic cutaneous squamous cell ...
JULY 7, 2020
FDA Approves Libtayo as First and Only Treatment for Advanced CSCC
Libtayo is a fully human monoclonal antibody that targets the immune checkpoint receptor PD-1 and works by blocking ...
SEPTEMBER 28, 2018
Load more